Headlines about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Stemline Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.8745387936377 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Stemline Therapeutics (STML) opened at $14.10 on Monday. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $16.20. The company has a market cap of $356.55, a PE ratio of -5.49 and a beta of -0.02.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative net margin of 4,689.63% and a negative return on equity of 75.50%. equities analysts predict that Stemline Therapeutics will post -2.71 earnings per share for the current year.
In other Stemline Therapeutics news, COO Kenneth Hoberman sold 11,943 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $14.18, for a total value of $169,351.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 37,966 shares of company stock valued at $534,848. 15.70% of the stock is owned by insiders.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with our FREE daily email newsletter.